09.14.21
Nutrasource Pharmaceutical and Nutraceutical Services, a global contract research organization, received a Controlled Drugs & Substances Dealer’s License from Health Canada, allowing the company to hold, distribute, and conduct clinical research on controlled substances. This is the first license obtained by a third-party, natural products-focused CRO in Canada, Nutrasource reports.
The license specifically will allows Nutrasource to work with clients to conduct early-stage clinical studies, including those on bioavailability and bioequivalence, proof of concept, and efficacy trials with controlled substances in Canada.
“With fully developed study protocols, safe storage, and management as well as an experienced QPIC (Qualified Person in Charge) recognized by Health Canada’s Office of Controlled Substances, Nutrasource is ready for controlled drug and substances projects,” Ana Samborski, pharmacy manager at Nutrasource, said.
“This license is an excellent and logical extension of our Institution-Wide Cannabis Research License obtained earlier this year,” William Rowe, Nutrasource President and CEO added. “Botanicals and their derivatives continue to be a key focus and these licenses enhance our position further in the nutra-to-pharma services pathway.
The license specifically will allows Nutrasource to work with clients to conduct early-stage clinical studies, including those on bioavailability and bioequivalence, proof of concept, and efficacy trials with controlled substances in Canada.
“With fully developed study protocols, safe storage, and management as well as an experienced QPIC (Qualified Person in Charge) recognized by Health Canada’s Office of Controlled Substances, Nutrasource is ready for controlled drug and substances projects,” Ana Samborski, pharmacy manager at Nutrasource, said.
“This license is an excellent and logical extension of our Institution-Wide Cannabis Research License obtained earlier this year,” William Rowe, Nutrasource President and CEO added. “Botanicals and their derivatives continue to be a key focus and these licenses enhance our position further in the nutra-to-pharma services pathway.